ABBVIE INC (ABBV)

US00287Y1091 - Common Stock

175.58  +4.06 (+2.37%)

After market: 175.58 0 (0%)

ABBVIE INC

NYSE:ABBV (12/20/2024, 8:04:00 PM)

After market: 175.58 0 (0%)

175.58

+4.06 (+2.37%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%1.69%
Sales Q2Q%3.83%
CRS54.32
6 Month3.05%
Overview
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)01-31 2025-01-31/amc
Ins Owners0.07%
Inst Owners73.38%
Market Cap310.27B
Shares1.77B
PE16.33
Fwd PE14.12
Dividend Yield3.82%
Analysts80
Short Float %1.09%
Short Ratio3.02
IPO01-02 2013-01-02
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABBV Daily chart

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. The company offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383 for the treatment of inflammatory bowel disease.

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS 60064

P: 18479327900

CEO: Richard A. Gonzalez

Employees: 50000

Website: https://www.abbvie.com/

ABBV News

News Image5 hours ago - The Motley Fool2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
News Imagea day ago - The Motley Fool3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
News Imagea day ago - Yahoo Finance3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

News Image3 days ago - The Motley Fool2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
News Image5 days ago - Market News VideoNoteworthy Tuesday Option Activity: ABBV, SLQT, TTD
News Image5 days ago - Investor's Business DailyAbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.

ABBV Twits

Here you can normally see the latest stock twits on ABBV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example